US6225310B1
(en)
|
1996-01-17 |
2001-05-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
AUPO227896A0
(en)
*
|
1996-09-13 |
1996-10-03 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel compounds and their preparation
|
ES2136013B1
(es)
*
|
1997-04-15 |
2000-07-01 |
Consejo Superior Investigacion |
Derivados de tieno y pirazolo (1,2,4) tiadiazina-1,1-dioxido farmacologicamente activos.
|
RU2215004C2
(ru)
*
|
1997-07-16 |
2003-10-27 |
Ново Нордиск А/С |
Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
|
WO1999032494A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
AU1649900A
(en)
*
|
1998-12-18 |
2000-07-12 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
US6329367B1
(en)
|
1998-12-18 |
2001-12-11 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
JP2002539202A
(ja)
*
|
1999-03-12 |
2002-11-19 |
ノボ ノルディスク アクティーゼルスカブ |
融合1,4−チアジン−2−カルボニトリル誘導体、その製造および使用
|
US6232310B1
(en)
|
1999-03-12 |
2001-05-15 |
Novo Nordisk A/S |
Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
|
US6197765B1
(en)
|
1999-06-08 |
2001-03-06 |
Pnina Vardi |
Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
|
JP2003525211A
(ja)
*
|
1999-06-30 |
2003-08-26 |
ノボ ノルディスク アクティーゼルスカブ |
新規方法
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AU2001265841A1
(en)
*
|
2000-06-26 |
2002-01-08 |
Novo-Nordisk A/S |
Use of potassium channel openers for the treatment of insulitis
|
AU2001265839A1
(en)
*
|
2000-06-26 |
2002-01-08 |
Novo-Nordisk A/S |
Use of potassium channel agonists for the treatment of cancer
|
CZ20031733A3
(cs)
|
2000-12-21 |
2003-09-17 |
Aventis Pharma Deutschland Gmbh |
Difenylazetidinonové deriváty a farmaceutické prostředky s jejich obsahem
|
WO2002050085A1
(en)
*
|
2000-12-21 |
2002-06-27 |
Novo Nordisk A/S |
A new process for preparing fused 1,2,4-thiadiazine derivatives
|
SK7822003A3
(en)
|
2000-12-21 |
2003-12-02 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
DE10110747A1
(de)
*
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
KR20040032937A
(ko)
|
2001-08-22 |
2004-04-17 |
아벤티스 파마 도이칠란트 게엠베하 |
1, 4-벤조티에핀-1, 1-디옥시드 유도체 및 기타 활성물질을 함유하는 배합 제제 및 이의 용도
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
IL160556A0
(en)
|
2001-08-31 |
2004-07-25 |
Aventis Pharma Gmbh |
Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Gmbh |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
US20030109519A1
(en)
*
|
2001-11-30 |
2003-06-12 |
Jeppe Sturis |
Use of selective potassium channel openers
|
AU2002342600A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
AU2002365289A1
(en)
*
|
2001-11-30 |
2003-06-10 |
Novo Nordisk A/S |
Use of selective potassium channel openers
|
RU2374236C2
(ru)
|
2001-12-21 |
2009-11-27 |
Ново Нордиск А/С |
Амидные производные в качестве активаторов gk
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
AU2003232171A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a beta cell resting compound
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
WO2004002481A1
(en)
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
NZ537603A
(en)
|
2002-07-12 |
2006-09-29 |
Sanofi Aventis Deutschland |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
CA2515368A1
(en)
*
|
2003-02-13 |
2004-08-26 |
Luciano Rossetti |
Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
EP1787982B1
(en)
|
2003-04-11 |
2010-05-12 |
High Point Pharmaceuticals, LLC |
11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
EP1670815A2
(en)
|
2003-09-30 |
2006-06-21 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
RU2386622C9
(ru)
|
2004-01-06 |
2021-04-21 |
Ново Нордиск А/С |
Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
US20050261292A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1アゴニストを用いた薬剤誘発性肥満の中和
|
DE102004042607A1
(de)
*
|
2004-09-03 |
2006-03-09 |
Bayer Healthcare Ag |
Substituierte Phenylaminothiazole und ihre Verwendung
|
WO2006041922A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Dara Biosciences, Inc. |
Agents and methods for administration to the central nervous system
|
CN101060856B
(zh)
|
2004-11-22 |
2011-01-19 |
诺和诺德公司 |
可溶、稳定的含胰岛素制剂
|
JP2008521864A
(ja)
|
2004-12-03 |
2008-06-26 |
トランステック・ファーマ、インコーポレイテッド |
ヘテロ芳香族グルコキナーゼ活性化剤
|
US8067362B2
(en)
|
2005-02-02 |
2011-11-29 |
Novo Nordisk As |
Insulin derivatives
|
US20080171695A1
(en)
|
2005-02-02 |
2008-07-17 |
Novo Nordisk A/S |
Insulin Derivatives
|
US20090012067A1
(en)
*
|
2005-02-14 |
2009-01-08 |
Luciano Rossetti |
Modulation of Hypothalamic Atp-Sensitive Potassium Channels
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
ES2449618T3
(es)
|
2005-06-30 |
2014-03-20 |
High Point Pharmaceuticals, Llc |
Ácidos fenoxiacéticos como activadores de PPAR-delta
|
WO2007003604A2
(en)
|
2005-07-04 |
2007-01-11 |
Novo Nordisk A/S |
Hists1mine h3 receptor antagonists
|
EP2377856A1
(en)
|
2005-07-14 |
2011-10-19 |
Novo Nordisk A/S |
Urea glucokinase activators
|
ES2426345T3
(es)
|
2005-07-20 |
2013-10-22 |
Eli Lilly And Company |
Compuesto unidos en posición 1-amino
|
PT1951658E
(pt)
|
2005-11-17 |
2012-11-12 |
Lilly Co Eli |
Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
|
EP2386540A1
(en)
|
2005-12-22 |
2011-11-16 |
High Point Pharmaceuticals, LLC |
Novel compounds, their preparation and use
|
EP2383271B1
(en)
|
2006-03-13 |
2013-07-10 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as GSK-3 Inhibitors
|
WO2007110364A1
(en)
|
2006-03-28 |
2007-10-04 |
High Point Pharmaceuticals, Llc |
Benzothiazoles having histamine h3 receptor activity
|
US8378097B2
(en)
|
2006-05-29 |
2013-02-19 |
High Point Pharmaceuticals, Llc |
3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
EP2061767B1
(de)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
|
DE102006042143A1
(de)
*
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
US7776178B2
(en)
*
|
2006-10-25 |
2010-08-17 |
Applied Materials, Inc. |
Suspension for showerhead in process chamber
|
US8022066B2
(en)
|
2006-11-15 |
2011-09-20 |
High Point Pharmaceuticals, Llc |
2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
DE102006056740A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
DE102006056739A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
DE102007035367A1
(de)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituierte Aryloxazole und ihre Verwendung
|
DE102007036076A1
(de)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid-Produgs und ihre Verwendung
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007042754A1
(de)
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
|
KR101563018B1
(ko)
|
2007-09-11 |
2015-10-23 |
교린 세이야꾸 가부시키 가이샤 |
Gsk-3 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
|
CN102344457B
(zh)
|
2007-09-12 |
2015-07-22 |
杏林制药株式会社 |
作为 gsk-3 抑制剂的螺环状氨基喹诺酮
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE102007061763A1
(de)
*
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte azabicyclische Verbindungen und ihre Verwendung
|
DE102007061756A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102007061757A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
|
DE102007061764A1
(de)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellierte Cyanopyridine und ihre Verwendung
|
DE102008008838A1
(de)
|
2008-02-13 |
2009-08-20 |
Bayer Healthcare Ag |
Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
|
DE102008013587A1
(de)
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
JP2011516610A
(ja)
*
|
2008-04-15 |
2011-05-26 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規な阻害剤
|
EP2297104B1
(de)
*
|
2008-05-29 |
2013-08-07 |
Bayer Intellectual Property GmbH |
2-alkoxy-substituierte dicyanopyridine und ihre verwendung
|
AR072707A1
(es)
|
2008-07-09 |
2010-09-15 |
Sanofi Aventis |
Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
|
WO2010059618A1
(en)
|
2008-11-21 |
2010-05-27 |
High Point Pharmaceuticals, Llc |
Adamantyl benzamide compounds
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
DE102008062566A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Aminosäureester-Prodrugs und ihre Verwendung
|
DE102008062567A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid-Prodrugs und ihre Verwendung
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
CA2755120C
(en)
|
2009-03-11 |
2017-05-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
RU2012111354A
(ru)
|
2009-08-26 |
2013-10-10 |
Санофи |
Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
|
KR20120091174A
(ko)
|
2009-10-02 |
2012-08-17 |
사노피 |
골질환 치료제의 제조를 위한 sglt-1/sglt-2 억제제 활성을 갖는 화합물의 용도
|
TW201121968A
(en)
*
|
2009-11-09 |
2011-07-01 |
Intermune Inc |
Novel inhibitors of hepatitis C virus replication
|
EP2539364A1
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20130143798A1
(en)
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
EP2687210A1
(de)
|
2010-06-25 |
2014-01-22 |
Bayer Intellectual Property GmbH |
Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
|
DE102010030688A1
(de)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Dicyanopyridine und ihre Verwendung
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
MX2013011175A
(es)
|
2011-03-28 |
2013-11-01 |
Novo Nordisk As |
Analogos de glucagon novedosos.
|
US9382305B2
(en)
|
2011-07-01 |
2016-07-05 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
KR20140039257A
(ko)
|
2011-07-08 |
2014-04-01 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
릴랙신을 방출하는 융합 단백질 및 이의 용도
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013144191A1
(de)
|
2012-03-29 |
2013-10-03 |
Bayer Intellectual Property Gmbh |
Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
|
EP2908825B1
(en)
|
2012-10-17 |
2018-04-18 |
Merck Sharp & Dohme Corp. |
Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
EP2908824B1
(en)
*
|
2012-10-17 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
WO2014093696A2
(en)
|
2012-12-12 |
2014-06-19 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
WO2014170496A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
EP3042658B1
(en)
|
2013-09-04 |
2019-01-16 |
Kyoto University |
Medicinal composition improving leptin resistance
|
CN105980374A
(zh)
|
2013-12-19 |
2016-09-28 |
拜耳制药股份公司 |
取代的哌啶基四氢喹啉
|
JOP20200052A1
(ar)
|
2013-12-19 |
2017-06-16 |
Bayer Pharma AG |
بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
|
EP3083610A1
(de)
|
2013-12-19 |
2016-10-26 |
Bayer Pharma Aktiengesellschaft |
Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
|
CA2934132A1
(en)
|
2013-12-19 |
2015-06-25 |
Bayer Pharma Aktiengesellschaft |
Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
EP3233087B1
(en)
|
2014-12-16 |
2019-10-02 |
Axovant Sciences GmbH |
Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
|
KR20180044256A
(ko)
|
2015-06-10 |
2018-05-02 |
엑소반트 사이언시즈 게엠베하 |
A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
|
US10428062B2
(en)
|
2015-08-12 |
2019-10-01 |
Axovant Sciences Gmbh |
Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
|
US20190008867A1
(en)
|
2015-11-13 |
2019-01-10 |
Ph Pharma Co., Ltd. |
4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
|
JP2020514365A
(ja)
|
2017-03-15 |
2020-05-21 |
ノヴォ ノルディスク アー/エス |
メラノコルチン4受容体に結合可能な二環式化合物
|
WO2019219714A1
(en)
|
2018-05-15 |
2019-11-21 |
Novo Nordisk A/S |
Compounds capable of binding to melanocortin 4 receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
WO2020165031A1
(de)
|
2019-02-15 |
2020-08-20 |
Bayer Aktiengesellschaft |
Substituierte isochinolin-piperidinylmethanon-derivate
|